BioWorld

Oct. 12, 2006

Genentech Earnings: Lucentis Strong, Oncology Weakening

Genentech Inc. beat expectations for the third quarter and posted strong sales of Lucentis, but weaker-than-expected performance from its oncology franchise cast a shadow over the numbers. (BioWorld Today) Read More

Striking Deals: Balance Of Power Shifting To Biotech?

Caprion, Centocor Sign Deal To Find Cancer Drug Targets

Antibacterial Firm Achaogen Gets $26M In Second Round

Other News To Note

Clinic Roundup

Today's news in brief

BioWorld

BioWorld briefs for Jan 9, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Jan. 9, 2026.

3D rendering of antibody drug conjugated with cytotoxic payload

ADCs’ breakout 2025 and their still-unfinished potential

BioWorld Science

Over the course of the year, and continuing into the latest scientific meetings, an extraordinary breadth of new antibody-drug conjugate (ADC) designs was...

Development and characterization of anti-CD19 in vivo CAR T therapy

BioWorld Science

Shenzhen Grit Biotechnology Co. Ltd. and Shanghai Vitalgen Biopharma Co. Ltd. recently presented their work to develop and evaluate a novel anti-CD19 in vivo CAR...

Preclinical results of anti-ADAMTS13 antibody in acquired von Willebrand syndrome

BioWorld Science

The acquired von Willebrand syndrome (AVWS) is a rare bleeding disorder with laboratory findings similar to those of inherited von Willebrand disease. Researchers...